France · Seed startup

Who invested in Diagnoly

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

AI

Funding summaryUpdated 26 Oct 2026

$6.0Mraised across 1 round since 2025, from 1 source

Latest round
Seed, $6.0MApr 2025
Investors
3
See who backed them

The rounds

  1. Apr 2025
    Seed$6.0M

    Source recorded

Founders and team

From Diagnoly's own website: 3 founders, 9 on the team.

Ivan VoznyukCEO & Co-Founder
Camille DupontCTO & Founding team member
Edwin QuarelloChief Medical Officer (CMO) & Co-Founder
  • Joseph AndréChief of staff
  • Damien LisseHead of Quality and Regulatory Affairs
  • Benoît B.Scientific Communication Manager
  • Lilou LouetUX/UI Designer
  • Marialuisa CatarinellaExecutive Office Manager
  • Marianna BeleteProduct Manager
  • Matthieu G.Senior Software Engineer
  • Rebecca HuberClinical Project Manager
  • Thomas GouletteRAQA Manager

Everyone who backed them

MassChallengeAccelerator1round
XAngeVC firm1round
Newfund CapitalVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Diagnoly

Who invested in Diagnoly?

Diagnoly's investors include MassChallenge, XAnge and Newfund Capital.

How much has Diagnoly raised?

Diagnoly has raised $6.0M across 1 round since 2025.

When did Diagnoly last raise?

Diagnoly's most recent round was a Seed of $6.0M in Apr 2025.

What was Diagnoly's biggest round?

Its most recent round, $6.0M in Apr 2025, is also its largest on record.

Who backed Diagnoly first?

Diagnoly's first round on record, in Apr 2025, was backed by MassChallenge, XAnge and Newfund Capital.

What stage is Diagnoly at?

Diagnoly's latest named round is a Seed, in Apr 2025.

Where is Diagnoly based?

Diagnoly is based in France.

Companies like Diagnoly

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.